Navigation Links
Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
Date:12/4/2014

MILPITAS, Calif., Dec. 4, 2014 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced the closing of the second tranche of its previously announced $18 Million Series B financing.  The company said these new funds would be used to advance the development of its recently nominated oral development candidate to Investigational New Drug (IND) filing and initiation of Phase 1 clinical trials in the second half of 2015.  Protagonist's development candidate, designated PTG-100, is an orally stable, alpha-4-beta-7 integrin specific antagonist peptide that has the potential of transforming the treatment paradigm for inflammatory bowel diseases (IBD) through its novel 'oral targeted therapy' approach.

"Alpha-4-beta-7 integrin is a clinically validated therapeutic target for IBD, a group of chronic, debilitating inflammatory conditions of the gastrointestinal tract, including Crohn's disease and ulcerative colitis, which represent major unmet and growing medical needs," said David Liu, Ph.D., Chief Scientific Officer of the Company. "Protagonist has applied its proprietary technology platform to discover novel, potent, target-specific and orally stable peptides against this IBD-specific target. Additionally, Protagonist has validated the critical hypothesis of treating IBD with an oral peptide antagonist with positive outcomes in numerous pharmacodynamic and efficacy studies in animal models of colitis, thereby leading to the nomination of its first development candidate."

"Securing the second tranche of our Series B financing is an acknowledgement of the progress that Protagonist Therapeutics has made in advancing not only the oral integrin blocker PTG-100, but also in creating a pipeline of additional pre-clinical stage assets such as the IL-23 receptor antagonist.  These programs are based on the concept of orally stable peptide therapeutics that have the combined oral stability characteristics of small molecule drugs with the potency and specificity of large biologics in a single new chemical entity (NCE)," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company engaged in the discovery and development of 'orally stable peptides' for inflammatory bowel diseases (IBD) and other gastrointestinal diseases and disorders.  The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides against protein-protein interaction (PPI) targets that are undruggable by small molecules and therefore have historically been approached only by 'injectable biologics'.  Oral peptides may lead to a superior and safer choice for IBD patients, physicians, and payers by virtue of their better convenience & compliance, favorable cost of goods, and potentially enhanced safety & efficacy in comparison to the injectable antibodies. The company is currently pursuing the IND-enabling studies of an alpha-4-beta-7 integrin-specific oral peptide antagonist PTG-100 and preclinical lead optimization of an oral IL-23 receptor antagonist as new chemical entities (NCEs) for the 'oral targeted therapy' based treatment of IBD.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and is headquartered in Milpitas, California USA and with discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

Logo - http://photos.prnewswire.com/prnh/20130501/MM06086LOGO


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
2. Protagonist Therapeutics Names David Liu Chief Scientific Officer
3. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
4. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
5. Pivotal Therapeutics Announces Third Quarter Accomplishments and Financial Results
6. Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
7. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
8. Relmada Therapeutics To Present At LD MICRO Conference
9. PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Councils 2014 Legend of Technology Award
10. Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
11. Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... , ... October 08, 2019 , ... ... at Western Pennsylvania & Ohio Valley Oral & Maxillofacial Surgery. This cutting-edge practice ... All-on-4® full arch dental implants to predictable jaw surgery with 3D ...
(Date:10/8/2019)... ... 08, 2019 , ... A free, interactive event highlighting innovations and ideas helping ... event, featuring thought leaders, innovators and health experts, will display innovations that could help ... to 5:30 p.m. CT on October 19 at the Coppertank Event Center in Austin, ...
(Date:10/8/2019)... ... , ... Corteva Agriscience and MicroMGx today announced a collaboration ... products. , Under the agreement, MicroMGx will apply its metabologenomics platform to accelerate ... agriculture industry, Corteva will use those starting points to discover and develop naturally ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... October 10, 2019 , ... Santa Rosa ... services for the healthcare industry, has completed the first phase of a comprehensive ... Commonwealth of The Bahamas towards a fully integrated health information management system (iHIMS). ...
(Date:10/10/2019)... ... October 10, 2019 , ... In ... 21 was excited to hear the significant results of an independent study presented ... of Nitrosigine®. The clinical study poster entitled “The Acute Effects of Citrulline Malate ...
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can three former Surgeons General ... wellness in the nation? That question will be answered at ICAA 2019: Shaping the ... Expo. The event will take place October 10-12, 2019, at the Gaylord Palms Resort ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... majority interest in Advanced Fertility Care (AFC), an advanced reproductive services (RE) facility ... expand the availability of RE services to expectant families throughout Arizona and the ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... services for the Department of Veterans Affairs Community Care Referrals and Authorizations program. ... of the VA’s Health Share Referral Manager (HSRM), an enterprise-wide system used by ...
Breaking Medicine News(10 mins):